Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Company Logo

Algernon’s business model is based on drug re-purposing, finding new uses for know drugs





 

Stock Quote Today & Recent News Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

"While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies, we announced that we plan to be the first company globally to investigate DMT for stroke and that is a goal that we are getting closer to achieving."

Christopher J. Moreau, CEO

Current News (CSE:AGN)

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

GlobeNewswire 5 days ago

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

GlobeNewswire April 1, 2024

Canadian Investment Regulatory Organization Trade Resumption - AGN

Canada NewsWire March 27, 2024

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

GlobeNewswire March 27, 2024

Canadian Investment Regulatory Organization Trading Halt - AGN

Canada NewsWire March 27, 2024

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

GlobeNewswire January 31, 2024
View More News ››

"Ifenprodil’s anti-tumour effect in this study is very impressive when you consider it does not appear to have the serious side effects typically seen with other chemotherapy agents.Our business plan is to have upwards of three to four Phase 2 trials underway in 2022 and we are very pleased to be adding Ifenprodil with a cancer indication to our pipeline.."

Christopher J. Moreau, CEO

Opinion & Analysis (CSE:AGN)

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

Dave Jackson June 16, 2021

Flying Under the Radar with a Possible COVID-19 Treatment

Stockhouse Editorial September 9, 2020

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Streetwise Reports May 29, 2020

Buzz on the Bullboards: Coronavirus, Esports, and Uranium Plays

Omri Wallach April 16, 2020

Buzz on the Bullboards: HOT Coronavirus Healthcare Stocks

Omri Wallach March 19, 2020
View More Opinion ››

"We are very pleased to be expanding our Ifenprodil cancer research program to include SCLC,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We also welcome Dr. William North to help us lead the investigation of Ifenprodil’s potential as a new non-toxic cancer therapy."

Christopher J. Moreau, CEO

Bullboard Posts (CSE:AGN)

Webinar $AGN CEO Chris Moreau Tue Apr 16 @ 4PM ET / 1PM PT

RESCHEDULED: Live Webinar - Algernon Pharmaceuticals $AGN w/ CEO Christopher Moreau Tuesday, April 16th at 4PM ET / 1PM PT Q&A...
bmreed - 6 days ago

Tuesday’s Trading

Out of the country so catching up . Tursday's trading brought the price by one cent and the usual kids in the sandbox were involved...
nodaytrader - March 21, 2024

Today’s Trading

Same old same old. Desjardins and National flinging nickels around like manhole covers.
nodaytrader - March 7, 2024

Today’s Trading

No Trading  in the sandbox today -unless you count the Quebec kids, Laurentian  and Desjardiin the 
nodaytrader - February 23, 2024

Today’s Trading

A busy day in the sandbox with over 100,000 shares traded. The Quebec kids were very active and the price dropped one cent today, like...
nodaytrader - February 6, 2024

Today’s Trading

Relatively big spread  bid and ask 08/095 for about four hours then three trades at $0.08 all from TDSecurities and all to the...
nodaytrader - February 5, 2024
View more Bullboard ››

Connect with C.AGN


PIPELINE TARGETED DISEASES MEDIA MANAGEMENT

CEO Clips: DMT Clinical Trial

CEO Q&A Interview with Chris Moreau

Investor Presentation

Download the latest Investor Presentaion

Algernon Highlights: The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Investment Opportunity

The Algernon Value Proposition



  • Advancing new drug treatments for billion dollar global disease markets.
  • Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues.
  • Conducting multiple phase II clinical trials.
  • Highly capital efficient business model.
  • Experienced management team & globally recognized medical advisory board.

Download the Presentaion

Facebook

Contact Us